NASDAQ:KYTX | Free Cash Flow | Kyverna Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$41.6M
2025-12-31-$33.53M-$1,000.00-$33.53M
2025-03-31-$44.92M$0.00-$44.92M
2024-12-31-$37.06M$532,000.00-$37.59M
2024-03-31-$25.53M$543,000.00-$26.07M
2023-12-31-$18.56M$334,000.00-$18.9M
2023-03-31-$11.46M$28,000.00-$11.49M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$153.71M$5,000.00-$153.72M
2024-12-31-$114.25M$2.21M-$116.46M
2023-12-31-$52.41M$621,000.00-$53.03M